Myeloma | Tumor

CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

January 13th 2022

In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.

A Lower Dose of Xpovio May Help Patients With Myeloma Get the ‘Full Benefit of the Drug’

January 13th 2022

Although patients with multiple myeloma may be concerned that a reduction in treatment dose may be less effective, an expert from The Tisch Cancer Institute stresses that it may be more beneficial.

FDA Target Dates for Potential Cancer Drug Approvals in Early 2022

January 10th 2022

The Food and Drug Administration is expected to decide on whether to approve certain cancer regimens within the first few months of the year. Here’s what patients with cancer should know.

Upfront Darzalex Combo May Be More Beneficial in the First-Line Setting for Transplant-Ineligible Myeloma Than Alternatives

January 5th 2022

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

The Most-Read Myeloma Stories of 2021

January 4th 2022

From an overview of the disease to notable deaths and clinicians who go the extra mile, here is a list of CURE®’s most-read myeloma articles from 2021.

Despite Full Vaccinations, Patients With Cancer Who Develop Breakthrough COVID-19 Infections May Still be at Risk for Severe Outcomes

December 24th 2021

Patients with cancer who received two full vaccine doses but developed breakthrough COVID-19 infections afterwards had a 13% mortality rate as well as a high hospitalization risk, and therefore should maintain protective strategies, according to experts.

Third Full Dose of COVID-19 Vaccine Increases Antibody Response in Patients with Blood Cancers

December 23rd 2021

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

FDA’s Approval of Subcutaneous Darzalex-Based Regimen Adds Another ‘Tool in the Toolbox’ to Treat Pretreated Myeloma

December 21st 2021

A certified oncology nurse and board-certified adult nurse practitioner explained how the recent FDA approval of Darzalex Faspro, Kyprolis and dexamethasone may allow patients with relapsed/refractory multiple myeloma to switch treatments after discovering their current treatment is no longer working.

CAR-T Cell Therapy Continues to Impress in Myeloma Treatment

December 15th 2021

Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.

Venclexta-Triplet Combo Appears Safe And Shows Deep Responses in Type of Relapsed/Refractory Multiple Myeloma

December 15th 2021

Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma.

Ninlaro-Darzalex Combo Elicits Favorable Treatment Outcomes, Responses in Newly Diagnosed Multiple Myeloma

December 13th 2021

Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

Cancer Clinical Trial Enrollment Is Low in the US, and Patient Depression and Anxiety May Play a Role

December 12th 2021

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

Dose Reduction of Xpovio Improves Safety and Optimizes Patient Outcomes in Myeloma

December 10th 2021

In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.

‘Cancer Fashionista’ Discusses Finding Confidence During Cancer

December 9th 2021

On this episode of the “Cancer Horizons” podcast, a woman with multiple myeloma shares how she made the best of her cancer treatment process by channeling her emotions through fashion expression.

FDA Approves Darzalex Faspro Plus Kyprolis and Dexamethasone for Myeloma Treatment

December 1st 2021

The FDA approved the three-drug regimen of Darzalex Faspro, Kyprolis and dexamethasone for patients with pretreated relapsed/refractory multiple myeloma.

Three-Drug Combo Meets ‘Gold Standard’ Overall Survival for Older Patients with Multiple Myeloma

November 23rd 2021

Darzalex plus Revlimid and dexamethasone may be the preferred option to treat older patients with multiple myeloma who are ineligible for stem-cell transplant.

CAR-T Cells, Bi-Specific Antibodies Find and Destroy Myeloma

November 19th 2021

An expert explains how two common myeloma treatments – CAR-T cell therapy and bi-specific antibodies – work, and which patients may want to steer clear from these treatment modalities.

The Myeloma Nurse Who Climbed a Mountain to Connect With Her Patients

October 22nd 2021

Myeloma survivors, their loved ones and clinicians trekked up the Alaska-Kenai Peninsula to raise money and funds for the disease, offering one nurse the inspiration she needed after more than a year of the COVID-19 pandemic.

The Future of Cancer Looks Bright With Engineered Cells

October 19th 2021

Engineered cell technology is an example of ingenuity that brings together cutting-edge laboratory science and clinical trials to address aggressive cancers.

Former Secretary of State Colin Powell Dies of COVID-19 Complications After Receiving Treatment for Cancer

October 18th 2021

Colin Powell has died of complications from COVID-19 after receiving treatment for a blood cancer.

Paying It Forward for Other Patients With Multiple Myeloma

October 18th 2021

After receiving a diagnosis of multiple myeloma, a patient relied on the Multiple Myeloma Research Foundation for information and is becoming part of the conversation.

A New Line of Defense in Blood Cancer: Natural Killer Cell Therapy

October 11th 2021

Natural killer cell therapy is making strides in blood cancer research, but there’s still much more to learn.

It Takes a Village: Cancer Caregivers Need to Care for Themselves, Too

October 7th 2021

Caregivers of patients with cancer may face financial toxicity and stress — with little time to take care of themselves.

It Takes Teamwork to Treat Myeloma, and Patients Are Key Players

October 5th 2021

Patients with myeloma should not be afraid to seek out second opinions or speak up about side effects that they are experiencing.

Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami

October 2nd 2021

View the full CURE® Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami on demand.

Age, Other Health Factors Can Play a Role in Cancer Treatment Decisions

September 23rd 2021

The prescription of systemic cancer therapies varies based on a patient’s age, comorbidities, cancer stage and other variables, according to recent research.

Patients With Blood Cancers and COVID-19 May Benefit From Convalescent Plasma Therapy

September 2nd 2021

The use of convalescent plasma therapy in patients with blood cancers and COVID-19 was associated with an improvement in survival from the infection.

Third Dose of COVID-19 Vaccine May Increase Protection in Immunocompromised Patients

August 19th 2021

Patients who are immunocompromised, such as patients with blood cancers, may get the boosted immunity needed to reduce their risk for contracting COVID-19 and hospitalization for compilations related to the virus.

COVID-19 Vaccine May Be Less Effective in Patients With Myeloma

July 31st 2021

Fifteen percent of patients with myeloma did not have detectable antibodies two weeks after receiving the COVID-19 vaccine.

FDA Warns Patients With Myeloma About Pepaxto: Drug Increased Death Rates in Clinical Trial

July 29th 2021

Patients with myeloma who are receiving Pepaxto should discuss the potential risks and benefits of continued treatment with the drug.

NEXT PAGE
PREVIOUS PAGE